Celmyo-35 Tablet is an oral hormonal combination, containing Ethinylestradiol and Cyproterone used to treat symptoms of polycystic ovary syndrome (PCOS) such as acne, excessive hair growth (hirsutism), and irregular periods. Polycystic ovary syndrome is a common condition, which affects how women's ovaries work.
Celmyo-35 Tablet is a combination of two hormonal medications, ethinylestradiol, and cyproterone used to treat PCOS symptoms such as acne, excessive hair growth (hirsutism), and irregular periods. Cyproterone, works by blocking a male hormone named androgen overproduction in the ovaries and reducing unwanted facial hair growth and acne. Ethinylestradiol, on the other hand, acts as an enhancer. It enhances the effect of cyproterone by reducing the amount of androgens in the blood. Collectively, they both effectively treat the symptoms of PCOS.
Celmyo-35 Tablet can be taken with or without food in dose and duration as prescribed by your doctor. For best results of Celmyo-35 Tablet , take it at the same time every day. Also, do not stop taking Celmyo-35 Tablet before completing its full course, even if you feel your symptoms are better. The most common side effects of Celmyo-35 Tablet include weight gain, nausea, tender breast, stomach pain, and headache. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects are persistent, reach out to your doctor. If you see swelling or pain in your limbs, chest pain, or shortness of breath, please inform your doctor.
Inform your doctor if your periods do not start within a week after taking Celmyo-35 Tablet . Do not take Celmyo-35 Tablet if you are pregnant already or breastfeeding. Celmyo-35 Tablet does not prevent the transmission of any sexually transmitted disease (STD), so use some other form of contraception (condom) during sexual intercourse if you have any STD or AIDS (acquired immunodeficiency syndrome). If you have any blood clots, please consult your doctor as Celmyo-35 Tablet may not be prescribed.